The Subjective Effects of Psychedelics May Not Be Necessary for Their Enduring Therapeutic Effects
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Psychedelics represent one of the most promising classes of experimental medicines for the treatment of neuropsychiatric disorders due to their ability to promote neural plasticity and produce both rapid and sustained therapeutic effects following a single administration. Conventional wisdom holds that peak mystical experiences induced by psychedelics are a critical component of their therapeutic mechanisms of action, though evidence supporting that claim is largely correlational. Here, I present data suggesting that the subjective effects induced by psychedelics may not be necessary to produce long-lasting changes in mood and behavior. Understanding the role of subjective effects in the therapeutic mechanisms of psychedelics will have important implications for both basic neuroscience and for increasing patient access to the next generation of medicines developed as a result of psychedelic research.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Whiteford, H. A., Degenhardt, L., Rehm, J., Baxter, A. J., Ferrari, A. J., Erskine, H. E., Charlson, F. J., Norman, R. E., Flaxman, A. D., Johns, N., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61611-6 · Cited by 6,006
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609
New approaches to antidepressant drug discovery: beyond monoamines
Berton, O., & Nestler, E. J. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1846 · Cited by 1,589
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Self-citationPsilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018
Roseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00974 · Cited by 808
Cited by
Items 201–300 of 344
Melani, A., Papini, G., Bonaso, M., Biso, L., Kolachalam, S., Bragazzi, N. L., Conversano, C., Orrù, G., Longoni, B., & Scarselli, M. (2026) · Biomedicines · doi:10.3390/biomedicines14030506 · Cited by 5
“In summary, current evidence supports a relevant association be-tween the subjective psychedelic experience and therapeutic outcomes [93], yet it remains unresolved whether this relationship is causal, modulatory, or epiphenomenal.”
Total Synthesis of Ervaoffine J and K
Hughes, A. J., & Townsend, S. D. (2024) · Chemistry - A European Journal · doi:10.1002/chem.202303985 · Cited by 5
The Psychedelic Renaissance: A Catholic Perspective
Carroll, T. (2024) · The Linacre Quarterly · doi:10.1177/00243639241274818 · Cited by 5
Psychedelics in Psychiatry: Oh, What A Trip!
Fonzo, G. A., Nemeroff, C. B., & Kalin, N. H. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20241025 · Cited by 5
Barker, S. A. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111259 · Cited by 5
Expectancies for Subjective and Antidepressant Effects in Psilocybin Users
Earleywine, M., Mian, M. N., & Leo, J. A. D. (2023) · Journal of Humanistic Psychology · doi:10.1177/00221678231194798 · Cited by 6
Photoswitchable TCB-2 for control of the 5-HT 2A receptor and analysis of biased agonism
Esmaeili, A. J., Montazeri, P., Gomez, J. C., Dumervil, D. J., Nezhad, F. S., & Steinhardt, R. C. (2024) · Chemical Communications · doi:10.1039/d4cc03892d · Cited by 5
Barber, M., Gardner, J., & Carter, A. (2022) · SSM - Qualitative Research in Health · doi:10.1016/j.ssmqr.2022.100202 · Cited by 5
Falcon, J. (2025) · Critique of Anthropology · doi:10.1177/0308275x251357813 · Cited by 4
“import via neurological activity (Olson, 2021).”
Meaning and Psychedelics in Palliative Care: A Narrative Review
Alexander, W. B., Hansen, E., Anderson, B. T., Zarrabi, A. J., Rogers, A. H., Loewen, G., Ficcaro, Z. R., Alexander, M. H., Schaefer, D., & Case, A. A. (2025) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2025.10.015 · Cited by 4
The utility of 2,5-dimethoxy-4-iodoamphetamine for the study of serotonin 2A and 2C receptors
Cameron, L. P., Jaster, A. M., Ramos, R., & Ullman, E. Z. (2025) · Molecular Pharmacology · doi:10.1016/j.molpha.2025.100093 · Cited by 4
Sanitizing psychedelics: the biopolitics of non-hallucinogenic psychoplastogens
Hartogsohn, I. (2026) · BioSocieties · doi:10.1057/s41292-025-00377-y · Cited by 5
Goldy, S. P., Sepeda, N. D., Hilbert, S. N., Bari, B. A., Garcia‐Romeu, A., Gukasyan, N., Barrett, F. S., Yaden, D. B., & Nayak, S. M. (2026) · Psychiatry Research · doi:10.1016/j.psychres.2026.117010 · Cited by 5
Bender, D. A., & Siegel, J. S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95702-1.00043-9 · Cited by 4
Leonard, D., & Brooks, T. R. (2025) · Journal of Humanistic Psychology · doi:10.1177/00221678251330066 · Cited by 4
Psychedelics for the treatment of end-of-life distress in patients with a life-threatening disease
Tap, S. C., Bostoen, T., Breeksema, J. J., & Schoevers, R. A. (2025) · International review of neurobiology · doi:10.1016/bs.irn.2025.03.001 · Cited by 4
Heal, D. J., Gosden, J., & Smith, S. L. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251382147 · Cited by 4
“The majority view is that the psychedelic experience is the source of the therapeutic effects (Kangaslampi, 2023; Ko et al., 2022; Romeo et al., 2025), though there are dissenting views (Olson, 2020).”
How to set up a psychedelic study: Unique considerations for research involving human participants
Glennon, M. J., Bird, C., Yadav, P., Kleine, P., Suseelan, S., Boman-Markaki, C., Kotoula, V., Butler, M., Leech, R., Roseman, L., et al. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106657 · Cited by 5
Unveiling the Psychedelic Journey: An Appraisal of Psilocybin as a Profound Antidepressant Therapy
Shah, F. I., Shehzadi, S., Akram, F., Haq, I. U., Javed, B., Sabir, S., Kazim, Y., & Ashfaq, S. (2023) · Molecular Biotechnology · doi:10.1007/s12033-023-00994-7 · Cited by 4
“The significance of the psychedelic sensation for the medicinal properties of psilocybin is still up for debate [75], and it will be the focus of subsequent research.”
Earleywine, M., Falabella, G. S., Oliva, A. B., & Low, F. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2421892 · Cited by 4
“Their necessity for subsequent improvements, their potential for replication, and their role in improving the lives of the general population have all generated critiques (e.g., Earleywine and Herrmann 2022; Koning and Brietzke 2023; Olson 2021).”
Complex emotional experiences: theoretical significance, ways of induction and therapeutic potential
Salikova, D. A., & Kosonogov, V. (2025) · Current Psychology · doi:10.1007/s12144-024-07207-7 · Cited by 4
“However, there is now the emergence of research on the “decomposition” of the psychedelic experience with the question: is it possible to isolate certain characteristics - those that make people feel better - and use them separately (Olson, 2020)?”
Synergistic behavioral and neuroplastic effects of psilocybin-NMDAR modulator administration
Tal, T. B., Pogodin, I., Botvinnik, A., Lifschytz, T., Heresco‐Levy, U., & Lerer, B. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03428-x · Cited by 4
“Nevertheless, it is presumed that SP ef fi cacy requires psychedelic effects, including alterations in consciousness and sensory perception, although this view is not held by all authors [8, 9].”
Traditional Amazonian medicine in addiction treatment: Qualitative results
O’Shaughnessy, D. M., Sarnyai, Z., Quirk, F. H., & Rodd, R. (2022) · SSM - Qualitative Research in Health · doi:10.1016/j.ssmqr.2022.100086 · Cited by 4
“…Hartogsohn, 2017; J. A. Olson et al., 2020; Perkins et al., 2021; Strickland et al., 2021), even though there are likely also pharmacological actions which support the process irrespective of context and subjective effects (Hesselgrave et al., 2021; Liester & Prickett, 2012; D. E. Olson, 2020).”
BackgroundFacilitating real-life creative insight through psychedelic virtual realityPreprint
Siimon, T., Tulver, K., Kaup, K., Vasser, M., & Aru, J. (2023) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/zth7f · Cited by 5
Serotonergic psychedelics for depression: A comprehensive overview
Wingert, A. M., Agnorelli, C., Peill, J., Reed, S., Nutt, D. J., & Erritzoe, D. (2025) · International Review of Neurobiology · doi:10.1016/bs.irn.2025.04.009 · Cited by 3
Pashdag, J. (2024) · Journal of Psychedelic Studies · doi:10.1556/2054.2024.00385 · Cited by 3
Psychedelic experiences in psychedelic-assisted therapy for depression
Khan, U. (2024) · Philosophical Psychology · doi:10.1080/09515089.2024.2378845 · Cited by 3
“Acknowledging that there is some debate about the issue (Olson, 2020), I assume the popular view which I call the psychedelic view – the subjective effects of psychedelics are important for their therapeutic benefits.”
Tavares, V. D. D. O., Gonçalves, K. T. D. C., Barros, M. L. D. M., de Brito, A. J. C., Cavalcanti-Ribeiro, P., Palhano-Fontes, F., Falchi-Carvalho, M., Nunes, E. A., Sarris, J. J., Perkins, D., et al. (2024) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001946 · Cited by 5
Psychedelic therapy: bridging neuroplasticity, phenomenology, and clinical outcomes
Kishon, R., & Cycowicz, Y. M. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1637162 · Cited by 3
“…psychedelic experience is necessary for therapeutic bene fi t, and some researchers advocate for non-hallucinatory psychedelics that eliminate it (68), clinical observations provide growing evidence suggesting that the quality and nature of the psychedelic experience itself critically predict…”
Barker, S. A. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00695 · Cited by 3
Oña, G. (2023) · Quaderns de l'Institut Català d'Antropologia · doi:10.56247/qua.401 · Cited by 4
“…aunque muy preliminares, de que los efectos subjetivos de estas sustancias pueden ser prescindibles para obtener efectos terapéuticos (Cameron et al., 2021; Hesselgrave et al., 2021; Olson, 2020), pese a que algunos autores afirman que estos efectos sí son necesarios (Yaden y Griffiths, 2021).”
Backgroundα-Ethyltryptamine: A Ratiocinatory Review of a Forgotten Antidepressant
Glennon, R. A., & Dukat, M. (2023) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00139 · Cited by 3
Hilal, F. F., Jeanblanc, J., & Naassïla, M. (2023) · Biologie Aujourd hui · doi:10.1051/jbio/2023028 · Cited by 4
Die Rolle der Psychotherapie in klinischen Studien mit Psychedelika
Evens, R., & Wolff, M. (2024) · Die Psychotherapie · doi:10.1007/s00278-024-00715-8 · Cited by 3
Attitudes of psychedelic users regarding cost of treatment and non-hallucinogenic alternatives
Aday, J. S., Boehnke, K. F., Herberholz, M., & Kruger, D. J. (2024) · Journal of Psychedelic Studies · doi:10.1556/2054.2024.00354 · Cited by 4
Licit use of illicit drugs for treating depression: the pill and the process
Pacheco, A. T., & Moghaddam, B. (2024) · Journal of Clinical Investigation · doi:10.1172/jci180217 · Cited by 3
“It has been suggested that dissociative effects of ketamine or mystical experiences of psilocybin may simply be an epiphenomenon and that they may not be required for the therapeutic effects of these drugs (63).”
BackgroundThe Promise of Psychedelic Research
Peritore, C. (2022) · Future Drug Discovery · doi:10.4155/fdd-2021-0012 · Cited by 3
Psychedelics, Atheism, and Naturalism Myth and Reality
Letheby, C. (2022) · Journal of Consciousness Studies · doi:10.53765/20512201.29.7.069 · Cited by 3
Petrovitch, D., Victor, S. E., Schmidt, A. T., Schmitz, J. M., Meyer, T. D., Stotts, A. L., & Littlefield, A. K. (2025) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-025-00371-y · Cited by 3
Bhatt, K. V., Compton, J. N., Ellerman-Tayag, E., Mishra, J., Perivoliotis, D., Pittman, J. O. E., Ramanathan, D., & Bismark, A. W. (2025) · Psychedelic Medicine · doi:10.1089/psymed.2024.0040 · Cited by 2
“13,14 Ketamine is a dissociative anesthetic that shares neurophysiological and phenomenological properties with psychedelics.”
Garcia‐Romeu, A. (2025) · NPP—Digital Psychiatry and Neuroscience · doi:10.1038/s44277-025-00043-y · Cited by 2
“Although these associations suggest some modest relationship between subjective effects and mental health improvements, it has been posited that such effects may be unnecessary and perhaps undesirable adverse effects [7].”
With great power comes great responsibility: Promise and caution in the new psychedelic renaissance
Halma, M. T. J., Levy, R., & Varón, J. (2025) · Brain Disorders · doi:10.1016/j.dscb.2025.100286 · Cited by 2
Li, S.-J., Yuan, Q., Wu, W.-Y., Tan, A., Chen, D., Chen, D., Shan, H., Hu, W., Hu, W., Wu, K., et al. (2025) · Research · doi:10.34133/research.0987 · Cited by 3
“…evidence suggests that the therapeutic efficacy of 5-HT 2A R agonists may not necessarily depend on psychedelic experiences, with studies demonstrating that psilocybin’s antidepressant effects can occur independently of both 5-HT 2A R activation and associated psychedelic activity [ 9 , 34 , 35 ].”
Lewis, B. R., Reid, M. C., Novick, A. M., Byrne, K., Niciu, M. J., Fonzo, G. A., Meyer, T. D., Feifel, D., El‐Mallakh, R. S., Soares, J., et al. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811251413490 · Cited by 3
“…experiential effects of classical psychedelics have been shown to correlate with therapeutic outcomes, there remain many questions as to the nature of this relationship and its consistency and therapeutic relevance (Goodwin et al., 2025; Ko et al., 2022; Olson, 2021; Yaden and Griffiths, 2021).”
Integrated 5-HT2A–TrkB and G protein signaling in serotonergic psychedelic responses
Taddei-Tardon, M., Medina-Rodríguez, L., Maltman, J. L., Hudson, S., Potukanuma, S., Jiménez, J. H., Martin-Guerrero, S. M., González‐Maeso, J., & López‐Giménez, J. F. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03746-6 · Cited by 4
“Whether the therapeutic efficacy of psychedelic compounds is associated with both of these responses, or primarily with the neuroplasticity-related component, remains a matter of considerable debate and active investigation [13, 14].”
A long trip into the universe: Psychedelics and space travel
Lerer, L. B., & Varia, J. C. (2022) · Frontiers in Space Technologies · doi:10.3389/frspt.2022.899159 · Cited by 2
“Psilocybin and other psychedelics increase synaptic density and neurogenesis and these neuroplastic effects are thought to be an important component of their therapeutic mechanism of action (Lima da Cruz et al., 2018; Hutten et al., 2020; Olson, 2020; Raval et al., 2021).”
BackgroundNasrallah, H. A. (2022) · Current Psychiatry · doi:10.12788/cp.0283 · Cited by 3
Timing is key for behavioural benefits of psychedelics
Woodburn, S. C., & Kwan, A. C. (2023) · Nature · doi:10.1038/d41586-023-01869-2 · Cited by 3
Schimmelpfennig, J., & Jankowiak-Siuda, K. (2023) · Neuropsychiatria i Neuropsychologia · doi:10.5114/nan.2023.129068 · Cited by 2
N -Cyclohexyltryptamine: freebase, bromide and fumarate
Naeem, M., Le, A. N., Bauer, B. E., Chadeayne, A. R., Golen, J. A., & Manke, D. R. (2023) · Acta Crystallographica Section E Crystallographic Communications · doi:10.1107/s2056989023006217 · Cited by 2
Utilization of Ketamine for Major Depression
Dao, R., & Aggarwal, A. (2023) · Journal of Exploratory Research in Pharmacology · doi:10.14218/jerp.2023.00027 · Cited by 2
Aghaei, A. M., Weleff, J., Martins, B. S., Ing, K., Fontenele, R., Barnett, B. S., Anand, A., & Nia, A. B. (2024) · Current Addiction Reports · doi:10.1007/s40429-024-00574-y · Cited by 2
“Furthermore, whether there is merit in pursuing biochemical research to discover compounds sharing a biological profile similar to psychedelics but lacking the capacity to induce altered mental status, hinges upon the answer to this pivotal question [23].”
InfluentialSynthesizing Attachment Theory with the REBUS Model: An Agenda Proposal for Psychedelic Science
Cherniak, A. D., Carhart-Harris, R. L., Brulin, J. G., Mikulincer, M., Östlind, S., & Granqvist, P. (2024) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780192844064.013.17 · Cited by 3
Koning, E., Chaves, C., Kirkpatrick, R. H., & Brietzke, E. M. (2024) · Journal of Eating Disorders · doi:10.1186/s40337-024-01185-8 · Cited by 2
Exploring the Role of Psychedelic Experiences on Wellbeing and Symptoms of Disordered Eating
Loh, N., & Luke, D. P. (2025) · Psychoactives · doi:10.3390/psychoactives4010007 · Cited by 2
“Furthermore, large scale studies of biochemical mechanisms underlying classic psychedelic-induced neuroplasticity and the non-addictive nature add weight to their therapeutic potential [104,105].”
Villiger, D. (2025) · Kennedy Institute of Ethics journal · doi:10.1353/ken.2025.a978176 · Cited by 3
Mystical Experience Induced by Esketamine Treatment: A Real-World Observational StudyPreprint
Mallevays, M., Fuet, L., Danon, M., Lodovico, L. D., Jaffré, C., Bouzeghoub, L., Mrad, S. M., Rousselet, A.-V., Allary, L., Müh, C., et al. (2026) · medRxiv · doi:10.64898/2026.03.31.26349757 · Cited by 2
Psychedelics: Recent Philosophical Discussions
Letheby, C. (2024) · Springer eBooks · doi:10.1007/978-94-017-8706-2_101-1 · Cited by 2
Kelly, T. J., & Liu, Q.-S. (2024) · Psychedelics. · doi:10.61373/pp024b.0019 · Cited by 1
Lee, Y., Arndt, S. V., Joji, C., Fleischer, H., Shelley, M., Liu, C., & Chang, Y. (2025) · International Journal of Mental Health and Addiction · doi:10.1007/s11469-025-01506-1 · Cited by 1
“These experiences, often described as mind-altering, have been linked to long-term positive outcomes for mental health, especially when used in conjunction with psychotherapy (Olson, 2020).”
Villiger, D. (2025) · Philosophy Compass · doi:10.1111/phc3.70059 · Cited by 1
“Should non‐subjective psychedelics, meaning drugs that have the therapeutic effects of psychedelics without psy-chedelic manifestations (cf. Olson 2021), become the default if they were discovered?”
Yan, K., Ni, C., Kuo, Y.-Y., & Chen, M. (2025) · European Journal for Philosophy of Science · doi:10.1007/s13194-025-00679-9 · Cited by 1
“…who adopt the drug-centered view argue that the therapeutic potential of psychedelics is best explained by their pharmacological properties alone; the subjective or hallucinogenic experience they induce is considered incidental, or even unnecessary, for achieving clinical benefits (Olson 2020).”
Beidas, Z., Ragnhildstveit, A., Blackman, A., Anderson, T., Fewster, E. C., Syed, O. A., Sobolenko, V., Kanca, I. K., Jaglinska, M., Son, T., et al. (2026) · BJPsych Open · doi:10.1192/bjo.2025.10968 · Cited by 1
“16,17 This is a particular consideration for individuals with emotion dysregulation, a core psychopathological feature of MDD, who may lack the necessary self-regulation skills to handle difficult and/or distressing psychedelic content (e.g. trauma or life issues) and states (e.g. confusion,…”
Bloy, C., Sarma, A., Marsh, B., Hardy, L., Grabski, M., Mollaahmetoğlu, Ö. M., Shotton, J., Bhaskaran, S., Lingford-Hughes, A. R., Curran, H. V., et al. (2026) · Addiction · doi:10.1111/add.70320 · Cited by 1
Psychedelic therapy and postpartum depression: priorities and prospects
Thuery, G., Crossen, F., McLoone, D., Hinds, C., Duffy, R. T., Jairaj, C., Harkin, A., & Kelly, J. R. (2026) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251408280 · Cited by 1
“88 In support of this is evidence that 5-HT 2A R antagonists abolish the head twitch response but not psilocybin-or LSD-induced plasticity or antidepressant-like effects in mice.”
Transient or transformative? Psychedelics, agency and informed consent
Caporuscio, C. (2026) · Journal of Medical Ethics · doi:10.1136/jme-2025-111248 · Cited by 1
Schlomberg, J. T., Meling, D., Grylka, R., Vasella, E. A., Augustinovic, D., & Scheidegger, M. (2026) · Scientific Reports · doi:10.1038/s41598-026-39261-5
Pottie, E., Vertriest, E., Martínez-Afani, D., Soares, B. A., Cassels, B. K., & Stove, C. P. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00352 · Cited by 1
Deutsch, A., Contreras, L. E., Kratina, S., & Mayo, L. M. (2026) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253261433836 · Cited by 1
“9 This debate becomes more complicated when we consider the differences in how psychedelics are defined and categorized.”
Carhart-Harris, R. L., Zeifman, R. J., Pasquini, L., Nandi, B., Rohani-Shukla, C., Suseelan, S., Mediano, P. A. M., Rosas, F. E., Timmermann, C., Kettner, H., et al. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1875339 · Cited by 1
“This bears relevance to the so-called “ non-psychedelic psychedelic ” debate (Carhart-Harris, 2023a), that is, the hypothesis that psychedelic subjective effects may be an undesirable and non-essential (e.g., epiphe-nomenal) component of the therapeutic action of psychedelics (Olson, 2020).”
Belinger, L., Rieser, N. M., Engeli, E., Becciolini, L., Clamote, M., Pribiš, M., Saissi, F., Florineth, G. A., Hehl, N. L., Herdener, M., et al. (2026) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2026.112879 · Cited by 1
Schmitz, C. N., Bernardic, M., Vlădoiu, A.-D., Harris, R., Carmana, D., Kärtner, L., Oberthür, G., Gründer, G., & Adolphi, H. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111873 · Cited by 2
Experience, plasticity, and context: Beyond single-level models of antidepressant action
Eckert, D. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261473402 · Cited by 1
Song, C., Chang, T., Buchborn, T., & Knöpfel, T. (2026) · Nature Communications · doi:10.1038/s41467-026-77238-0 · Cited by 1
“Indeed, this has been a matter of intense debate in the psychedelic fi eld 1,47,48 .”
If psychedelics heal, how do they do it?
Beans, C. M. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2321906121 · Cited by 1
Introduction: philosophy and psychedelic psychiatry
Letheby, C., & Gerrans, P. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780192898371.003.0001 · Cited by 1
A Needs Assessment of Older Hispanics in Omaha, Nebraska
DiMartino, D. R. (1979) · DigitalCommons@UNO · Cited by 1
The promises and pitfalls of facilitated spiritual experiences for the study of religion
Morgan, J. (2022) · Religion Brain & Behavior · doi:10.1080/2153599x.2022.2091008 · Cited by 1
Therapeutic dissociation: From non-ordinary states to psychological transformationPreprint
Clingo, J. (2024) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/ypr7w · Cited by 1
Zeifman, R. J. (2024) · doi:10.32920/26052859.v1 · Cited by 1
Serotonergic Polypharmacology of 2-Halogenated TryptaminesPreprint
Yacoub, J., Bray, E., Bayyat, J., Glatfelter, G. C., Leake, A., Buitrago, E. M., Maitland, A. D., Partilla, J. S., Cavalco, N. G., Schalk, S. S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.16.718915 · Cited by 1
Orlowski, P., Ruban, A., Szczypiński, J., Hobot, J., Bielecki, M., & Bola, M. (2021) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/k4xfg
“It had been proposed that subjective aspects of psychedelics intake might not be necessary for at least some treatment effects to occur (Olson, 2021).”
BackgroundThe therapeutical role of psychedelic drugs in treatment of mental disorders
Oprea, D. C., Epure, L., Chiriță, V., & Cantemir, A. (2021) · Bulletin of Integrative Psychiatry · doi:10.36219/bpi.2021.3.09
Pardo, B., Kilmer, B., Ramchand, R., & Farmer, C. M. (2022) · RAND Corporation eBooks · doi:10.7249/pea1363-6
Regulatory, Ethical and Political Challenges of Experimentation with LSD on Human Subjects
Bodnár, J. K., & Peter, S. (2022) · Springer eBooks · doi:10.1007/978-3-030-99680-2_22
Pursuit of the Miraculous or Just Piling up Confusion
Caldararo, N. (2022) · Springer eBooks · doi:10.1007/978-3-031-13745-7_3
Caldararo, N. (2022) · Springer eBooks · doi:10.1007/978-3-031-13745-7_1
Traitements psychédéliques et soins en addictologie
Dauré, C., & Mallet, L. (2023) · Elsevier eBooks · doi:10.1016/b978-2-294-77934-3.00069-x
Breeksema, J. J. (2024) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.912040905 · Cited by 1
Neural effects of psychedelics: Complexity the key word
Jones, B. D. M., & Husain, M. I. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-024-01856-9
Schaller, A., Bourquin, G., Araujo, I. A., & Ljuslin, M. (2023) · Revue internationale de soins palliatifs · doi:10.3917/inka.242.0098
Petrovitch, D., Mitchell, S. M., Allen, J. V., & Littlefield, A. K. (2024) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/adnpg
Ferreira, A. S. M., Martindale, S., & Luke, D. P. (2024) · Journal of Psychedelic Studies · doi:10.1556/2054.2024.00368
“…results seem to support that, on the one hand, the mediation of meaningful subjective effects might not be needed to produce therapeutic responses (Olson, 2021), but they may be needed for the responses to be whole and enduring (Yaden & Grif fi ths, 2021): in fact, he reported that after the 2…”
BackgroundAssisted Psychedelic Psychotherapy: Rethinking the Paradigms of Psychiatric Care?
Mea, E., & Clemente, P. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1008154
CNS Biased Agonism and the Promise of Targeting Drugs Beyond Receptors to Cellular Pathways
Melnick, L. M. (2024) · Springer eBooks · doi:10.1007/978-3-031-61992-2_9
Psychedelic Drugs as Treatment Agents
Yehuda, R., Lepow, L., Bonnano, P. A., Zaretsky, T. G., Antonio, J. H., & Jagodnik, K. M. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780197640654.003.0074
Flameling, L. J. (2025) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/b6tvz_v1
Metadata
- Authors
- Olson, D. E.
- Affiliations
- University of California, Davis (US)
- Corresponding author
- Olson, David E.
- ORCID
- Olson, David E.
- Venue
- ACS Pharmacology & Translational Science
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-12-10
- Volume
- 4
- Issue
- 2
- Pages
- 563-567
- ISSN
- 2575-9108 (ISSN-L)
- PMC
- PMC8033607
- OpenAlex
- W3112904824
- Cited by
- 329
- References
- 36
- Citations by year
- 2026: 43 · 2025: 70 · 2024: 69 · 2023: 55 · 2022: 58 · 2021: 31 · 2020: 2
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- ACS Pharmacology & Translational Science (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (R01GM128997)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
- Keywords
- psychedelics, subjective effects, mystical experience, mood, behavior, neuroplasticity, neuropsychiatric disorders, psychedelic medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.